

November 12, 2008

AnGes MG, Inc.

Termination of Joint Development with Alfresa Pharma Corporation

Alfresa Pharma Corporation (Alfresa Pharma) and AnGes MG, Inc. (AnGes MG) have been engaged in joint development in Japan on atopic dermatitis therapy using NF- κ B decoy oligodeoxynucleotide. Both parties have now agreed to terminate this joint development. Following this outcome, AnGes MG now plans to appoint a new partner and move on to Phase III Clinical Trials in Japan.

Termination of the joint development will not affect the consolidated earnings forecast for FY 2008 and there will be no revision to the forecast.

- Company Profile -

Company name	: Alfresa Pharma Corporation
Headquarters	: 2-2-9 Kokumachi, Chuo-ku, Osaka
Representative	: Tetsuo Kure
Established	: December 24, 1939
Capital	: 1 billion yen (March 31, 2008)
Number of employees	: 636 (March 31, 2008)
Sales	: 24 billion and 704 million yen (term ending March 2008)
Scope of Business	: Manufacture, import, export and marketing of pharmaceuticals, diagnostic products, medical devices, pharmaceutical raw materials, etc.
Major shareholder	: Alfresa Holdings Corporation (100%)

###